| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | John R Petrie | |
| James G Boyle | |||
| Rachel Livingstone | |||
| REMOVAL Study Team | |||
| P2860 | cites work | Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011) | Q26863741 |
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010 | Q28254978 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study | Q33375701 | ||
| Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. | Q51325737 | ||
| The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes. | Q51489748 | ||
| Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. | Q51554552 | ||
| Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. | Q53648299 | ||
| Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135 | Q88362274 | ||
| Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients | Q93620474 | ||
| Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. | Q33705903 | ||
| The use of metformin in type 1 diabetes: a systematic review of efficacy | Q34091638 | ||
| Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data | Q34249847 | ||
| Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study | Q34288242 | ||
| Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study | Q34440576 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial | Q36633074 | ||
| Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up | Q36820594 | ||
| The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis | Q36824770 | ||
| Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks? | Q36898042 | ||
| Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus | Q37239783 | ||
| Perivascular fat, AMP-activated protein kinase and vascular diseases. | Q37671282 | ||
| Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial | Q37710285 | ||
| Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications | Q38197344 | ||
| Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus | Q38382871 | ||
| Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial | Q38399028 | ||
| Metformin: clinical use in type 2 diabetes. | Q38645273 | ||
| Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial | Q38725515 | ||
| Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. | Q39159983 | ||
| AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study | Q39765196 | ||
| Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study | Q39839307 | ||
| Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. | Q41686216 | ||
| The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being | Q42607898 | ||
| Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial | Q43524137 | ||
| The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients | Q44231029 | ||
| Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial | Q44262745 | ||
| Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells | Q44468960 | ||
| Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity | Q44599557 | ||
| Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes | Q44882775 | ||
| Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. | Q45950896 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | metformin | Q19484 |
| type-1 diabetes | Q124407 | ||
| amidines | Q423088 | ||
| anti-diabetic medication | Q575062 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2017-08-02 | |
| 2017-09-01 | |||
| P1433 | published in | Diabetologia | Q5270140 |
| P1476 | title | A new perspective on metformin therapy in type 1 diabetes |
| Q48004902 | 60 years of metformin use: a glance at the past and a look to the future |
| Q48302673 | A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for Adjunctive Metformin? |
| Q55317609 | Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes. |
| Q55234623 | Adjunctive therapy for glucose control in patients with type 1 diabetes. |
| Q47568289 | Latent autoimmune diabetes of adulthood: case report |
| Q90301380 | Mechanisms of action of metformin with special reference to cardiovascular protection |
| Q89490717 | Metformin and cardiorenal outcomes in diabetes: A reappraisal |
| Q51744512 | Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. |
| Q57314980 | Streptozotocin-induced β-cell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain |
| Q64262232 | Vascular biomedicine in an era of chronic disease and multimorbidity |
Search more.